Fewer biopharma deals and a smaller upfront total in Q3 for the lowest since 2018

https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/jpmorgan-chase-q3-2023-biopharma-final-ada_v2.pdf